jethro
Distinguished member
- Joined
- Nov 2, 2017
- Messages
- 457
- Reason
- PALS
- Diagnosis
- 09/2017
- Country
- HR
- State
- Croatia
- City
- ZAGREB
let's say there are 5 PALS@100000. statistic data say less (2--3@100000), but there are many poor, old, sick from other diseases etc.
it means that there are on earth max 500000 pals (according to official data 100-200000). 90% cannot afford themselves drug which is permanent and cost (lets say) 1000 usd/month (radicava), espetially people from asia, india, china etc... clinical cost for a new drug in phase 2 are app 20mil usd, and phase 3 is 30-50mil usd (prices are for ALS). cheapest are phases 1 and 4. how many people have 2500 usd/55days for radicava? rilutek is useless and costs in europe app 200 usd/month, and many eastern europeans have no even such a money. is it daemon who can heal tennis players, rugby, basketball and other players? what to expect from nurown, which is, as far as i know, only drug in phase III? i understand why gm604 wont enter phase III, pay i.e. 25mil usd being refused by fda. it needs time, pharmaceutical companies, certain people and some things to bring up drug which maybe already exists.
it means that there are on earth max 500000 pals (according to official data 100-200000). 90% cannot afford themselves drug which is permanent and cost (lets say) 1000 usd/month (radicava), espetially people from asia, india, china etc... clinical cost for a new drug in phase 2 are app 20mil usd, and phase 3 is 30-50mil usd (prices are for ALS). cheapest are phases 1 and 4. how many people have 2500 usd/55days for radicava? rilutek is useless and costs in europe app 200 usd/month, and many eastern europeans have no even such a money. is it daemon who can heal tennis players, rugby, basketball and other players? what to expect from nurown, which is, as far as i know, only drug in phase III? i understand why gm604 wont enter phase III, pay i.e. 25mil usd being refused by fda. it needs time, pharmaceutical companies, certain people and some things to bring up drug which maybe already exists.